Molnupiravir + Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Coronavirus Disease (COVID-19)
Conditions
Coronavirus Disease (COVID-19)
Trial Timeline
Aug 11, 2021 → Nov 16, 2022
NCT ID
NCT04939428About Molnupiravir + Placebo
Molnupiravir + Placebo is a phase 3 stage product being developed by Merck for Coronavirus Disease (COVID-19). The current trial status is completed. This product is registered under clinical trial identifier NCT04939428. Target conditions include Coronavirus Disease (COVID-19).
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06667700 | Phase 3 | Recruiting |
| NCT04939428 | Phase 3 | Completed |
| NCT04575597 | Phase 2/3 | Completed |
| NCT04575584 | Phase 2/3 | Terminated |
Competing Products
20 competing products in Coronavirus Disease (COVID-19)